Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform
Costello R, Waller K, Smith R, Mells G, Wong A, Schultze A, Mahalingasivam V, Herrett E, Zheng B, Lin L, MacKenna B, Mehrkar A, Bacon S, Goldacre B, Tomlinson L, Tazare J, Rentsch C. Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform. Communications Medicine 2024, 4: 238. PMID: 39562612, PMCID: PMC11576861, DOI: 10.1038/s43856-024-00664-y.Peer-Reviewed Original ResearchCOVID-19 hospitalisationSevere COVID-19 outcomesCOVID-19 related hospitalisationCOVID-19 outcomesCohort studyPopulation-based cohort studyHazard ratioPrimary care recordsDeath registration dataOpenSAFELY-TPP platformApproval of NHS EnglandConfidence intervalsEstimate hazard ratiosCox proportional hazards regressionProportional hazards regressionPre-specified confoundersAbsolute risk reductionOpenSAFELY platformCare recordsNHS EnglandConfounder adjustmentEligible individualsRegistration dataHazards regressionHospital records